Conferences - Results from #8360

#ASCO14 - Poster: Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel June 3, 2014

#ASCO14 - Poster: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo June 3, 2014

#ASCO14 - Poster: Enzalutamide monotherapy: 1-year extended follow-up of a Phase 2 study in hormone-naive prostate cancer patients June 3, 2014

#ASCO14 - Poster: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel June 3, 2014

#ASCO14 - Poster: Predicting response to abiraterone acetate: mRNA biomarker analysis of study COU-AA-302 June 3, 2014

#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial June 3, 2014

#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy June 2, 2014

#ASCO14 - Poster: Symptomatic skeletal events in patients with advanced prostate cancer: Results from a phase 3 trial of denosumab for the prevention of skeletal-related events June 2, 2014

#ASCO14 - Poster: Patient-reported quality of life analysis of radium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCA study June 2, 2014

#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide... June 2, 2014

#ASCO14 - Poster: 15-year survival outcomes following primary androgen deprivation therapy for localized prostate cancer June 2, 2014

#ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED June 2, 2014

#ASCO14 - Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: An ECOG-led phase III randomized trial - Session Highlights June 2, 2014

#ASCO14 - Poster: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study June 1, 2014

#ASCO14 - Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights June 1, 2014

#ASCO14 - Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma - Session Highlights June 1, 2014

#ASCO14 - Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study - Session Highlights June 1, 2014

#ASCO14 - Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer (UBC) - Session Highlights June 1, 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer June 1, 2014

#ASCO14 - Poster: Circulating tumor cell count and lactate dehydrogenase levels are prognostic factors in patients with metastatic CRPC progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial May 31, 2014

Page 419 of 481

email news signup